Trial site
Toowoomba Hospital
Toowoomba, Queensland 4350, AustraliaNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 23 trials
- Phase 1/21 trial
- Status
- Recruiting7 trials
- Active, not recruiting5 trials
- Completed2 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Lead sponsor
- Amgen3 trials
- Boehringer Ingelheim2 trials
- Eli Lilly and Company2 trials
- Australasian Gastro-Intestinal Trials Group1 trial
- Australian and New Zealand Intensive Care Research Centre1 trial
- and 8 more
Running trials
Recruiting
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649· Phase 3· Pfizer· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Vikas Garg (principal investigator)
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756· Phase 3· Eli Lilly and Company· Source
Contact: Vikas Garg (principal investigator)
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079· Phase 2· Australasian Gastro-Intestinal Trials Group· Source
Contact: A/Prof Matthew Burge
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
NCT05180942· Monash University· Source
Active, not recruiting
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
NCT04569942· Phase 3· Australian and New Zealand Intensive Care Research Centre· Source
Active, not recruiting
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707· Phase 3· UMC Utrecht· Source
Contact: Cameron Green, MSc
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error